Bergen, Norway, 15 April 2024 - Reference is made to the stock exchange
announcement published by BerGenBio ASA (the "Company") on 15 June 2023
regarding the allocation of offer shares and warrants (the "Warrants") to
certain primary insiders and close associates of primary insiders of the Company
in connection with the June 2023 rights issue completed pursuant to a resolution
by the Company's annual general meeting on 22 May 2023. Reference is further
made to the Company's stock exchange announcement published on 2 April 2024
regarding the commencement of the second exercise period for the Warrants. Each
Warrant gives the holder a right to subscribe for one new share ("New Share") in
the Company. The Warrants are listed and tradable on the Oslo Stock Exchange
until 16:30 hours (CEST) on 8 April 2024 under the ticker code "BGBIS".

The Company has been informed that Sarsia Seed AS, a company closely related to
Sveinung Hole, Board member and primary insider of BerGenBio ASA, has exercised
4,050,000 Warrants, for the allocation of 4,050,000 New Shares in the Company at
a price per New Share of NOK 0.1255.

Please see further details about the transaction in the attached form.

The New Shares issued upon exercise of Warrants will be listed on the Oslo Stock
Exchange under ISIN NO 001 0650013 and ticker code "BGBIO". The New Shares will
be listed as soon as the New Shares have been registered in the VPS and the
share capital increase pertaining to the New Shares have been registered with
the Norwegian Register of Business Enterprises.

The New Shares may not be transferred or traded before they are fully paid.

Subject to timely payment of the subscription price for the New Shares on 19
April 2024, the Company expects the share capital increase pertaining to the
exercise of Warrants to be registered with the Norwegian Register of Business
Enterprises on or about 23 April 2024 and that the New Shares will be delivered
to the VPS accounts of the subscribers to whom they are allocated on or about 24
April 2024.

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.